Day: February 9, 2022

REHOVOT, Israel, Feb. 09, 2022 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced financial results for the year and the six months ended December 31, 2021. “We achieved significant progress in the advancement of our promising oncology pipeline during this year with notable data releases in both of our lead candidates,” said Gil Efron, President and Chief Financial Officer of Purple Biotech. “For NT219, we are currently treating patients in the fourth dose cohort monotherapy arm of the ongoing Phase 1/2 clinical trial and have initiated the first dose level in the combination arm of the study together with...

• FDA Agreed to PolyPid Request for the Addition of an Unblinded Interim Analysis in SHIELD I once 750 Patients Complete their 30–day Follow-up • Recruitment Progressing as Planned with Approximately 680 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery. Expect to Reach 750 Enrolled Patients by End of First Quarter 2022 and Have Unblinded Interim Analysis During the Second Quarter of 2022 • Recently Completed Planned 500–Patient Blinded Sample Size Reassessment of SHIELD I Supports the Continuation of the Trial• Conference Call Scheduled for Today at 8:30 AM ET   PETACH TIKVA, Israel, Feb. 09, 2022 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release...

NEW HAVEN, Conn., Feb. 09, 2022 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, will present at the upcoming SVB Leerink 11th Annual Global Healthcare Conference on Wednesday, February 16 at 2:20 p.m. ET. Dr. Mehta will highlight the Company’s neuroscience and immuno-oncology programs, artificial intelligence platform used to augment and accelerate the drug candidate discovery and development process, and its commercial and launch readiness plans for BXCL501. To access the live webcast of the presentation and the Company’s accompanying presentation materials, please visit “News/Events”...

CAMBRIDGE, Mass. and BOULDER, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins, Chief Executive Officer and President, will participate in a fireside chat during the 11th Annual SVB Leerink Global Healthcare Conference, taking place virtually February 14 – 18, 2022. The fireside chat will stream live Wednesday, February 16 at 10:00 a.m. ET, after which a recording will be available to conference attendees for 90 days. Links to the webcast and recording registration page can be found under the “Events” tab on the investor relations section of the Cogent Biosciences website at: https://investors.cogentbio.com/events. About Cogent Biosciences, Inc. Cogent Biosciences is...

Rego Payment Architectures, Inc Poised to Accelerate Growth Rego Payment Architectures Inc, patented privacy-first platform and award winning super app, Mazoola® recognized as first and only COPPA and GDPR certified family mobile wallet BLUE BELL, Pa., Feb. 09, 2022 (GLOBE NEWSWIRE) — Rego Payment Architectures, Inc. (“REGO”) (OTCQB:RPMT), today announced the appointment of fintech veteran, Stuart C. Harvey Jr., as Chairman of Board of Advisors. With a 30-year track record of driving accelerated growth in payments and financial services, and extensive corporate and capital markets expertise, Harvey brings a wide range of experience to help craft and champion REGO’s next phase of growth. Harvey has been on the forefront of driving business and technology solutions in fintech with previous roles as CEO of Elavon Global Acquiring...

TORONTO, Feb. 09, 2022 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that the Company’s common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States (“US”). DTC is a subsidiary of the Depository Trust & Clearing Corp., which manages the electronic clearing and settlement of publicly traded companies in the US. DTC eligibility incorporates an electronic method of clearing securities that accelerates the receipt of stock and cash, reduces costs, and allows the stock to be traded over a much wider selection of brokerage firms by meeting their clearing and settlement requirements. Warwick...

– In vitro studies indicate IGM-6268 exhibits potent neutralization activity against the Omicron variant and all other Variants of Concern and Variants of Interest tested – – IGM-6268 Phase 1 clinical trials advancing in U.S. and South Africa – MOUNTAIN VIEW, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its progress in two Phase 1 clinical trials evaluating IGM-6268, an anti-SARS-CoV-2 IgM monoclonal antibody, for the treatment and prevention of COVID-19. The first, a Phase 1 clinical trial in the U.S., is a multi-center, randomized, double-blinded, placebo-controlled single (SAD) and multiple (MAD) ascending dose study to assess the safety, tolerability, and pharmacokinetics of...

SAN DIEGO and TAICANG, China, Feb. 09, 2022 (GLOBE NEWSWIRE) — Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Dr. Zheng Wei, Co-Founder & CEO, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 4:20 pm ET. A webcast of this fireside chat will be available on the Company’s Investor Relations page accessible here: https://investors.connectbiopharm.com/. A replay will be available on the Company’s website following the event. About Connect Biopharma Holdings LimitedConnect...

11th Largest Craft Brewer in the U.S., SweetWater, Launches Partnership with the Country’s Largest Beer Distributor, Reyes Beer Division West Coast Expansion Makes its Way Across the Coast After 25 Years ATLANTA, Feb. 09, 2022 (GLOBE NEWSWIRE) — SweetWater Brewing Company, LLC (“SweetWater”), a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), has announced its landmark expansion across the state of California with distribution partners, Reyes Beer Division, tying together the continued westward expansion of the SweetWater brand with the opening of SweetWater Colorado Brewing Company, LLC in Fort Collins, Colorado, and the recent acquisition of San Diego beer brands, Alpine Beer Company and Green Flash Brewing Company. With this expansion, the nation’s 11th largest craft brewer will now be available for...

Highlights:Two new Dorman® OE FIX™ labor-saving flexible stainless steel braided fuel lines for 2.5+ million General Motors vehicles First-to-aftermarket suspension stabilizer bar bracket kits for 19 million aging Ford, GM, Jeep and Hummer vehicles Turbocharger boost solenoid valves that replace original equipment valves prone to failure on 2+ million Buick, Chevrolet, and Ford vehiclesCOLMAR, Pa., Feb. 09, 2022 (GLOBE NEWSWIRE) — Dorman Products, Inc. (NASDAQ:DORM) is announcing today the release of more than 400 new auto parts, including nearly 200 new-to-the-aftermarket parts that advance the company’s mission of giving repair professionals and vehicle owners greater freedom to fix a wide range of cars and trucks. Dorman continues to provide consumers and service technicians aftermarket choices for common failures on millions...